| 证券代码 | CMTA.O |
| 证券名称 | Clementia Pharmaceuticals Inc |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2017-08-02 |
| 首发价格(元) | 15 USD |
| 首发数量(股) | 8000000 |
| 首发募资额(元) | 120,000,000.00 USD |
| 首发主承销商 | Morgan Stanley & Co. LLC,Leerink Partners LLC |
| 货币单位 | USD |
| 公司名称 | Clementia Pharmaceuticals Inc. |
| 注册地址 | 加拿大魁北克省 |
| 办公地址 | 4150 Sainte-Catherine Street West, Suite 550, Montreal, Quebec, Canada |
| 成立日期 | 2010-11-05 |
| 董事会主席 | David P. Bonita |
| 公司属地 | Canada 加拿大 |
| 公司网址 | www.clementiapharma.com |
| 电话 | +1 (514) 940-3600 |
| 传真 | - |
| 公司简介 | Clementia Pharmaceuticals Inc. is a clinical stage biopharmaceutical company that is developing disease-modifying treatments for patients suffering from debilitating bone and other diseases with high unmet medical need. Its lead product candidate, palovarotene, is an oral small molecule that binds and activates retinoic acid receptor gamma (an RARg agonist), and has shown potent activity in preventing abnormal new bone formation as well as scar tissue formation (or fibrosis) in a variety of tissues in animal models. |